Drugs / DM-101PX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06037148 | Sep 2023 → Mar 2024 | — | Desentum Oy | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07254871 | Sep 2025 → Apr 2026 overdue | — | Desentum Oy | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Desentum Oy | Results New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX desentum.fi ↗
The study showed that a short course of only 10 weekly injections was well tolerated and induced a strong and functional immune response. |
| 2025-08-27 | Desentum Oy | Regulatory Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada desentum.fi ↗
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2 clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. |
| 2025-05-16 | Desentum Oy | Results Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress desentum.fi ↗
Subcutaneous AIT with a thermosensitive hydrogel formulation containing genetically engineered Bet v 1 is safe and induces a strong protective immune response in birch pollen allergic patients |
| 2025-04-02 | Desentum Oy | Results Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX desentum.fi ↗
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. |
| 2023-09-14 | Desentum Oy | Regulatory Desentum received clinical trial approval from Health Canada desentum.fi ↗
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation intended for immunotherapeutic treatment of birch pollen allergy. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM-101PX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07254871 ↗ |
| Route | Subcutaneous | “subcutaneous injection of DM-101PX” NCT06037148 ↗ |